Genoskin at the SOT 64th Annual Meeting and ToxExpo
Advancing non-clinical toxicity assessment with ex vitro human skin and mast cell models
We are excited to participate in the SOT 64th Annual Meeting and ToxExpo, taking place from March 16-20, 2025, at the Orange County Convention Center in Orlando, Florida.
As one of the most influential events in toxicology, this meeting gathers leading experts from academia, industry, and regulatory agencies to discuss the latest advancements in toxicological sciences. This year, Genoskin is presenting two scientific posters, showcasing how our ex vivo human skin and mast cell platforms provide relevant human data for immunogenicity and toxicity assessment.
Our poster presentations at SOT 2025
1. Longitudinal maintenance of human skin viability in HypoSkin®
Abstract #1963 | Poster Board #3677/A137
Session Date & Time: March 18, 2025 | 1:45 PM – 4:15 PM
Our HypoSkin® platform demonstrates a 7+ days viability of human skin tissue ex vivo, allowing for longitudinal assessments of wanted and off-target immune responses. Using multiomic profiling and the example of an on-market injectable vaccine, this study demonstrates how HypoSkin can support drug development applications, from vaccines immunogenicity assessment to immunotoxicity evaluations.
2. Human primary mast cells as an advanced model for drug development
Abstract #1965 | Poster Board #3244/G369
Session Date & Time: March 17, 2025 | 1:45 PM – 4:15 PM
Mast cells play a critical role in immune modulation, allergic reactions, and inflammation, making them essential in assessing drug safety and efficacy. Our research highlights the use of human primary mast cells as a reliable in vitro platform to assess compound-induced toxicity, mast cells-related immune reactions, and drug safety in a human-relevant system.
Expanding toxicology research with human-relevant models
As regulatory agencies push for New Approach Methodologies (NAMs) to reduce reliance on animal testing, human-based platforms like HypoSkin® and our human primary mast cells provide predictive and ethical solutions for assessing immunotoxicity at the injection site.
Our ex vivo models bridge the gap between preclinical studies and human outcomes, offering robust alternatives for toxicology research in pharmaceuticals, biologics, and chemical formulations.
Join us at the SOT 64th annual meeting & ToxExpo
We invite attendees to visit our poster presentations and connect with us to explore how our ex vivo human skin and mast cell platforms can enhance your toxicity and immunogenicity research.
Stay tuned for more updates, and if you’re attending SOT this year, don’t miss the chance to engage with our team!
Comments are closed.
